Medical device company Integra LifeSciences (NASDAQ: IART) will be reporting earnings tomorrow morning. Here’s what to expect.
Integra LifeSciences missed analysts’ revenue expectations last quarter, reporting revenues of $402.1 million, up 5.6% year on year. It was a softer quarter for the company, with revenue guidance for next quarter missing analysts’ expectations significantly and a significant miss of analysts’ revenue estimates.
Is Integra LifeSciences a buy or sell going into earnings? Read our full analysis here, it’s free for active Edge members.
This quarter, the market is expecting Integra LifeSciences’s revenue to decline 2.7% year on year, a reversal from the 11.5% increase it recorded in the same quarter last year.
Analysts covering the company have generally reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. Integra LifeSciences has missed Wall Street’s revenue estimates multiple times over the last two years.
Looking at Integra LifeSciences’s peers in the healthcare equipment and supplies segment, some have already reported their Q4 results, giving us a hint as to what we can expect. Intuitive Surgical delivered year-on-year revenue growth of 18.8%, beating analysts’ expectations by 1%, and Envista reported revenues up 15%, topping estimates by 10.6%. Intuitive Surgical’s stock price was unchanged after the resultswhile Envista was up 17.8%.
Read our full analysis of Intuitive Surgical’s results here and Envista’s results here.
Investors in the healthcare equipment and supplies segment have had fairly steady hands going into earnings, with share prices down 1.9% on average over the last month. Integra LifeSciences is up 5.7% during the same time and is heading into earnings with an average analyst price target of $15.50 (compared to the current share price of $11.70).
P.S. STOP buying the AI stocks everyone's talking about. The real money? It’s in the profitable pick nobody’s watching yet. We’ve identified an AI profit machine that’s flying under Wall Street’s radar—for now. We can’t keep this research public forever—grab your FREE copy before we pull it offline. GO HERE NOW.
